Giapreza (angiotensin II)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- angiotensin II
- Company
- Paion Pharma GmbH
- Status
- Authorised
- Therapeutic area
- Hypotension; Shock
- CHMP opinion
- Thu 27 Jun 2019
- EU approval
- Fri 23 Aug 2019
- Designations
- Additional monitoring
- Application
- EMEA/H/C/004930
- ATC
- C09
- Official record
- www.ema.europa.eu
Indication
Giapreza is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies.
Regulatory milestones
No milestones recorded in the last year.
Follow Giapreza
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.